Evidence map›Paper›PMID 31139950›Full record

ArticleRheumatology international2019

Associations of cigarette smoking with disease phenotype and type I interferon expression in primary Sjögren's syndrome.

Peter Olsson, Iris L A Bodewes, Anna M Nilsson, Carl Turesson, Lennart T H Jacobsson, Elke Theander, Marjan A Versnel, Thomas Mandl

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Peter OlssonDepartment of Clinical Sciences, Malmö, Rheumatology, Lund University, Malmö, Sweden. peterx.olsson@med.lu.se.ORCID http://orcid.org/0000-0001-7318-833X
Iris L A BodewesDepartment of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0001-5206-4231
Anna M NilssonDepartment of Clinical Sciences, Malmö, Rheumatology, Lund University, Malmö, Sweden.
Carl TuressonDepartment of Clinical Sciences, Malmö, Rheumatology, Lund University, Malmö, Sweden.ORCID http://orcid.org/0000-0002-3805-2290
Lennart T H JacobssonDepartment of Clinical Sciences, Malmö, Rheumatology, Lund University, Malmö, Sweden.
Elke TheanderDepartment of Clinical Sciences, Malmö, Rheumatology, Lund University, Malmö, Sweden.
Marjan A VersnelDepartment of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.ORCID http://orcid.org/0000-0003-0245-5386
Thomas MandlDepartment of Clinical Sciences, Malmö, Rheumatology, Lund University, Malmö, Sweden.ORCID http://orcid.org/0000-0002-7143-7088
Lund University · SEMalmö University · SE

Funding

Greta och Johan Kocks stiftelser 9420180916000Reumatikerförbundet 834211Stiftelsen Sjögrens syndrom .
6 · The paper itself

Abstract

Several studies have shown a negative association between smoking and primary Sjögren's syndrome (pSS), and smoking may interfere with the immune response. The purpose of this study was to investigate if smoking affects disease activity and disease phenotype in pSS. In this cross-sectional study, consecutive pSS patients filled out the EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) form and a structured questionnaire regarding smoking habits. EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) scores were calculated and blood samples were analysed for type I interferon signature using RT-PCR. Of 90 patients (93% women, median age 66.5 years), 72% were type I IFN signature positive and 6, 42 and 53% were current, former and never smokers, respectively. No significant differences by smoking status were found regarding ESSDAI total score, activity in the ESSDAI domains or type I IFN signature. Patients with a higher cumulative cigarette consumption (≥ median) had higher scores in ESSPRI total [5.0 (3.0-6.3) vs 8.0 (6.0-8.3); p < 0.01] and ESSPRI sicca and pain domains. Comparing type I IFN signature negative and positive patients, the latter had significantly lower activity in ESSDAI articular domain (7/25 vs 3/64; p < 0.01) and lower scores in ESSPRI total [7.7 (5.2-8.2) vs 6.0 (4.0-7.7); p = 0.04]. Smoking was not associated with disease phenotype although patients with a higher cumulative cigarette consumption had worse symptoms in some disease domains. Current smokers were few making it difficult to draw any firm conclusions about associations to current smoking.

Indexed as

SmokersAgedBiomarkersCigarette SmokingCross-Sectional StudiesFemaleHumansInterferon Type IMaleMiddle AgedPhenotypeRisk FactorsSeverity of Illness IndexSjogren's SyndromeBiomarkersInterferon Type IAutoimmune diseasesCigarette smokingInterferon type ISjogren’s syndrome

Identifiers

PMID31139950
OpenAlexW2947106371

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.